Clinical Trial Results:
A trial comparing the efficacy and safety of once weekly dosing of somapacitan with daily Norditropin® in Chinese children with growth hormone deficiency
Summary
|
|
EudraCT number |
2020-002974-28 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
18 Dec 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Jul 2024
|
First version publication date |
04 Jul 2024
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
NN8640-4468
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04970654 | ||
WHO universal trial number (UTN) |
U1111-1250-7530 | ||
Sponsors
|
|||
Sponsor organisation name |
Novo Nordisk A/S
|
||
Sponsor organisation address |
Novo Alle, Bagsvaerd, Denmark, 2880
|
||
Public contact |
Clinical Reporting Office (2834), Novo Nordisk A/S, clinicaltrials@novonordisk.com
|
||
Scientific contact |
Clinical Reporting Office (2834), Novo Nordisk A/S, clinicaltrials@novonordisk.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
05 Feb 2024
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
18 Dec 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To compare efficacy of somapacitan vs Norditropin on longitudinal growth in Chinese children with growth hormone deficiency (GHD)
|
||
Protection of trial subjects |
The trial was conducted in accordance with the Declaration of Helsinki (October 2013) and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (November 2016) including archiving of essential documents.
|
||
Background therapy |
Not applicable | ||
Evidence for comparator |
Not applicable | ||
Actual start date of recruitment |
22 Jul 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
China: 110
|
||
Worldwide total number of subjects |
110
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
110
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
The trial was conducted at 20 sites in China. | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
A total of 110 subjects were randomised in a 2:1 ratio to receive either somapacitan or Norditropin. | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Norditropin | |||||||||||||||||||||
Arm description |
Subjects received Norditropin 0.034 milligrams per kilogram (mg/kg) subcutaneously (s.c.) once daily with prefilled pen-injector for 52 weeks. | |||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||
Investigational medicinal product name |
Norditropin
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
Norditropin FlexPro
|
|||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||||||||
Dosage and administration details |
Norditropin 0.034 milligrams per kilogram (mg/kg) given subcutaneously (s.c.) once daily with prefilled pen-injector for 52 weeks.
|
|||||||||||||||||||||
Arm title
|
Somapacitan | |||||||||||||||||||||
Arm description |
Subjects received somapacitan 0.16 milligrams per kilogram (mg/kg) s.c. once weekly with prefilled pen-injector for 52 weeks. | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Somapacitan
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
Sogroya
|
|||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||||||||
Dosage and administration details |
Somapacitan 0.16 milligrams per kilogram (mg/kg) given s.c. once weekly with prefilled pen-injector for 52 weeks.
|
|||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Norditropin
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received Norditropin 0.034 milligrams per kilogram (mg/kg) subcutaneously (s.c.) once daily with prefilled pen-injector for 52 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Somapacitan
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received somapacitan 0.16 milligrams per kilogram (mg/kg) s.c. once weekly with prefilled pen-injector for 52 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Norditropin
|
||
Reporting group description |
Subjects received Norditropin 0.034 milligrams per kilogram (mg/kg) subcutaneously (s.c.) once daily with prefilled pen-injector for 52 weeks. | ||
Reporting group title |
Somapacitan
|
||
Reporting group description |
Subjects received somapacitan 0.16 milligrams per kilogram (mg/kg) s.c. once weekly with prefilled pen-injector for 52 weeks. |
|
|||||||||||||
End point title |
Height Velocity | ||||||||||||
End point description |
Height velocity (HV) at week 52 is reported and was derived from height measurements taken at baseline and week 52 visit in the following way: HV = (height at 52 weeks visit - height at baseline)/(time from baseline to 52 weeks visit in years). Full analysis set included all subjects randomised. Number of Subjects Analyzed = subjects who were evaluated for this endpoint.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Height velocity (annualised) at week 52
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical analysis 1 | ||||||||||||
Statistical analysis description |
Height velocity at 52 weeks was analysed using a mixed model for repeated measurements, with treatment, gender, age group, growth hormone peak group and gender by age group interaction term as factors and baseline height as a covariate, all nested within week as a factor.
|
||||||||||||
Comparison groups |
Norditropin v Somapacitan
|
||||||||||||
Number of subjects included in analysis |
103
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority [1] | ||||||||||||
Method |
|||||||||||||
Parameter type |
Treatment difference | ||||||||||||
Point estimate |
0.6
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.2 | ||||||||||||
upper limit |
1.3 | ||||||||||||
Notes [1] - The non-inferiority margin of -2.0 cm/year was used in the trial. Subjects in this analysis were 110 (as analysis is based on repeated measurements, all data till week 52 is included in the analysis), incorrectly displayed as 103. |
|
|||||||||||||
End point title |
Change in Height Standard Deviation Score (HSDS) | ||||||||||||
End point description |
Change from baseline in HSDS at week 52 is reported. HSDS was derived using Chinese general population standards as reference data. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. Positive value in change from baseline in HSDS indicated that HSDS was better than baseline HSDS. Data is reported for 'on-treatment' observation period. On-treatment observation period: from first administration and up until last trial contact, visit 7 (week 52) or 14 days after last administration, whichever came first. Full analysis set included all subjects randomised. Number of Subjects Analyzed = subjects who were evaluated for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline (week 0) to week 52
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change in Bone Age | ||||||||||||
End point description |
Change in bone age from visit 1 (week -14) to week 52 is reported. X-rays of left hand and wrist for bone age assessment according to the Greulich and Pyle atlas were taken. Data is reported for 'on-treatment' observation period. On-treatment observation period: from first administration and up until last trial contact, visit 7 (week 52) or 14 days after last administration, whichever came first. Full analysis set included all subjects randomised. Number of Subjects Analyzed = subjects who were evaluated for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From visit 1 (week -14) to week 52
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change in Height Velocity Standard Deviation Score (HV SDS) | ||||||||||||
End point description |
Change from baseline in HV SDS at week 52 is reported. HV SDS was derived using Prader standards as reference data & calculated as (height velocity - mean)/standard deviation (SD), where height velocity (HV) was the HV variable measured, mean and SD of HV by gender and age for the reference population. The range for HV SDS was -10 to +10. Negative scores indicated a HV below the mean HV for a child with the same age and gender, whereas positive scores indicated a HV above the mean HV for a child with the same age and gender. Positive value in change from baseline in HV SDS indicated that HV SDS was better than baseline HV SDS. Data is reported for 'on-treatment' observation period. On-treatment observation period: from first administration and up until last trial contact, visit 7 (week 52) or 14 days after last administration, whichever came first. Full analysis set included all subjects randomised. Number of Subjects Analyzed = subjects who were evaluated for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline (week 0) to week 52
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change in Glycated Haemoglobin (HbA1c) | ||||||||||||
End point description |
Change from baseline in HbA1c at week 52 is reported. Data is reported for 'on-treatment' observation period. On-treatment observation period: from first administration and up until last trial contact, visit 7 (week 52) or 14 days after last administration, whichever came first. Safety analysis set included all subjects randomly assigned to trial treatment & who took at least 1 dose of trial product. Number of Subjects Analyzed = subjects who were evaluated for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline (week 0) to week 52
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change in Fasting Plasma Glucose (FPG) | ||||||||||||
End point description |
Change from baseline in FPG at week 52 is reported. Data is reported for 'on-treatment' observation period. On-treatment observation period: from first administration and up until last trial contact, visit 7 (week 52) or 14 days after last administration, whichever came first. Safety analysis set included all subjects randomly assigned to trial treatment & who took at least 1 dose of trial product. Number of Subjects Analyzed = subjects who were evaluated for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline (week 0) to week 52
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change in Insulin-like Growth Factor I (IGF-I) Standard Deviation Score (SDS) | ||||||||||||
End point description |
Change from baseline in IGF-I SDS at week 52 is reported. The range for IGF-I SDS was from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. For subjects with low IGF-I SDS at baseline, a positive change from baseline in IGF-I SDS indicated a better outcome. Data is reported for 'on-treatment' observation period. On-treatment observation period: from first administration and up until last trial contact, visit 7 (week 52) or 14 days after last administration, whichever came first. Full analysis set included all subjects randomised. Number of Subjects Analyzed = subjects who were evaluated for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline (week 0) to week 52
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change in Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Standard Deviation Score (SDS) | ||||||||||||
End point description |
Change from baseline in IGFBP-3 SDS at week 52 is reported. The range for IGFBP-3 SDS was from -10 to +10. Negative scores indicated a IGFBP-3 below the mean IGFBP-3 for a child with the same age and gender, whereas positive scores indicated a IGFBP-3 above the mean IGFBP-3 for a child with the same age and gender. For subjects with low IGFBP-3 SDS at baseline, a positive change from baseline in IGFBP-3 SDS indicated a better outcome. Data is reported for 'on-treatment' observation period. On-treatment observation period: from first administration and up until last trial contact, visit 7 (week 52) or 14 days after last administration, whichever came first. Full analysis set included all subjects randomised. Number of Subjects Analyzed = subjects who were evaluated for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline (week 0) to week 52
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to week 70
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
All presented adverse events are treatment emergent, defined as adverse events with onset after the first administration of trial product & up until 14 days after last trial drug administration. Safety analysis set included all subjects randomly assigned to trial treatment & who took at least 1 dose of trial product.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
somapacitan
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received somapacitan 0.16 milligrams per kilogram (mg/kg) s.c. once weekly with prefilled pen-injector for 52 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Norditropin
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received Norditropin subcutaneous (s.c.) 0.034 milligrams per kilogram (mg/kg) once daily with prefilled pen-injector for 52 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |